Home » Reports » USA Broker Ratings » Zosano Pharma Corp 175% Potential Upside Now Implied by ROTH Capital

Zosano Pharma Corp 175% Potential Upside Now Implied by ROTH Capital

Zosano Pharma Corp with TICKER NASDAQ:ZSAN had its stock rating noted as ‘Reiterated’ with the recommendation being set at ‘BUY’ today by analysts at ROTH Capital. Zosano Pharma Corp are listed in the Health Care sector within NASDAQ. ROTH Capital have set a target price of 11 USD on its stock. This indicates the analyst believes there is a potential upside of 175% from today’s opening price of 4 USD.

Zosano Pharma Corp NASDAQ:ZSAN has a 50 day moving average of 8.26 USD and a 200 day moving average of 9.33 USD. The 52 week high share price is 12.4 USD while the year low share price is currently 3.43 USD. Over the last 30 and 90 trading days the company share price has decreased 4.1 points and decreased 5.45 points respectively. There are currently 12,552,313 shares in issue with the average daily volume traded being 12,410. Market capitalisation for NASDAQ:ZSAN is $54,149,423.00 USD.

 

Zosano Pharma Corp NASDAQ:ZSAN is a clinical-stage specialty pharmaceutical company. The company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers rapid onset, consistent drug delivery and improved ease of use and room-temperature stability. Its microneedle patch system has the potential to deliver numerous medications for a range of indications in commercially attractive markets. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an existing drug and attached to an adhesive patch. Its lead product candidates, and the indications they are expected to treat include Daily ZP-PTH, for severe osteoporosis; ZP-Glucagon, for severe hypoglycemia, and ZP-Triptan, for migraine.

Join us on our new LinkedIn page

Follow us on LinkedIn